In Switzerland, OA was approved by the regulatory agency (Swissmedic) in July 2021 for the treatment of individuals with 5q-associated SMA below age 2 years and a clinical diagnosis of SMA type 1 or SMA patients with no more than 3 SMN2 gene copies. Here, SMN2 is linked to proximal spinal muscular atrophy.